- The Molecular Biology of HIV/AIDS
- The epigenetics of cancer, a recent view
- Rolling Circle Amplification Technology–Technical Details
- Structure of an enzyme and its in hibitor
- Cancer as a Disease of the Cell Cycle
- Development and morphogenesis: potentialities from common patterns
- Employment Opportunities
- Employment Opportunities at MSI
- PROPERTIES OF DNA
- HYBRIDIZATION METHODS IN LIQUID PHASE
- Human skin analysis
- The mitofusin 2 in mitochondrial energization
- Induction therapy of autophagy and apoptosis in melanoma cells
- Apoptotic mechanisms of granzymes in CTL lysis
- Parallel evolution of the venom of snakes and integrin
Parallel evolution of the venom of snakes and integrin
Structural Proteomics Group, Institute of Biomedicine of Valencia (CSIC) develops several years studies on the evolution and functional characteristics of different proteins from the venom of snakes, from the Mediterranean region. These proteins selectively block the function of cell surface receptors of the integrin family.
Becoming available and genomic libraries of tissues and many different agencies. In this case, researchers in Valencia have been cloned and sequenced cDNA fragments of the venom-producing gland in Cerastes Viper and short disintegrins encoding and subunits of dimeric disintegrins. From the analysis of messenger RNA conclude that these molecules could be distributed over a larger number of tissue than initially believed. Furthermore, sequence comparison suggests a common ancestor for short disintegrins for dimeric disintegrins precursor chains.
The most interesting part of the study is that for the first time, shows the parallel evolution of the blocking sequence of the disintegrins from the venom of snakes and integrin alpha chains, which are cellular receptors. Also presented are specific patterns of evolutionary adaptation of the antagonists of snake venom ligand regions of the integrin receptor.
These studies are also directly related to the laboratory can produce potent inhibitors of angiogenesis, which could be used in the design of new ant tumor drugs directed against surface receptors of cancer cells.